Venous thrombosis
Drug research and approvals for venous thrombosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 194 studies of venous thrombosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, FDA has 1 approved and 0 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 194
- Trials authorized in Canada: 7
- FDA orphan approvals: 1
- EU medicines: 1
Recruiting Now
Newest start dates first, of 194 recruiting on ClinicalTrials.gov ↗- Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein…NCT07776080 · Phase 2 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · starts Oct 1, 2026
- Comparison of DOACs and LMWH for Thromboprophylaxis After Total Knee ArthroplastyNCT07869615 · Not applicable · Military Hospital of Tunis · starts Sep 15, 2026
- Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a…NCT07697599 · Phase 3 · Regeneron Pharmaceuticals · starts Sep 7, 2026
- Clinical Trial of Thrombectomy SystemsNCT07749820 · Not applicable · BrosMed Medical Co., Ltd · starts Aug 30, 2026
- Circadian Variation of Anti-Factor Xa in Hospitalized Trauma PatientsNCT07856641 · Not reported · The University of Texas Health Science Center, Houston · starts Aug 26, 2026
- Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic…NCT07493304 · Phase 3 · Regeneron Pharmaceuticals · starts Aug 26, 2026
- The GORE® VIABAHN® FORTEGRA Venous Stent Post-Approval StudyNCT07538609 · Not applicable · W.L.Gore & Associates · starts Aug 25, 2026
- Smart Technology Facilitated Patient-centered Care for Patients With Pulmonary ThromboembolismNCT06382038 · Not applicable · Navy General Hospital, Beijing · starts Aug 20, 2026
- The Influence of Plan B® on Cardiovascular Health.NCT07759635 · Not applicable · McMaster University · starts Jul 22, 2026
- Pulmonary Embolism in Patients With Acute Heart Failure (PEHF Study)NCT07499661 · Not applicable · University Hospital, Angers · starts Jul 15, 2026
Trials Authorized in Canada
Newest first; search them all in Canada trials| Sep 25, 2026 | Open-label, multi-center, single-dose phase 1 study to investigate the pharmacokinetics, safety, and tolerability of milvexian in pediatric patients from 28…MILVEXIAN (BMS-986177, JNJ-70033093) | Johnson & Johnson | Pending |
| May 2, 2024 | A randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of bay 3018250 in patients with symptomatic proximal deep…BAY 3018250 | Bayer | Closed |
| Dec 24, 2020 | A randomized controlled trial on the use of postoperative extended venous thromboprophylaxis in patients with inflammatory bowel disease. a pilot studyAPIXABAN | MCMASTER UNIVERSITY | Ongoing |
| Sep 18, 2018 | Treatment of portal, mesenteric, and splenic vein thrombosis with rivaroxaban. a pilot, prospective cohort study.RIVAROXABAN | OTTAWA HOSPITAL RESEARCH INSTITUTE | Closed |
| Apr 20, 2018 | Perioperative ischemic evaluation-3 (poise-3) trialTRANEXAMIC ACID | HAMILTON HEALTH SCIENCES CORPORATION | Closed |
| Dec 18, 2015 | 7-day study of the safety, efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in children from birth to less than 6 months…XARELTO (RIVAROXABAN, BAY 59-7939) | Bayer | Closed |
| Oct 2, 2015 | 30-day, open-label, active-controlled, randomized study of the safety, efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in…XARELTO (RIVAROXABAN, BAY 59-7939) | Bayer | Closed |
FDA Orphan Designations
Approved first, then open designations, newest first| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Mar 30, 2007 | CeprotinPrevention and treatment of venous thrombosis and purpura fulminans | Baxalta US, Inc. | Approved |
Medicines Authorised in the EU
Newest first| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Mar 20, 2002 | Arixtrafondaparinux sodium | Viatris Healthcare Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA